股份回购

Search documents
东方生物: 第三届监事会第十二次会议决议公告
Zheng Quan Zhi Xing· 2025-06-27 16:29
Group 1 - The company plans to repurchase its shares using an amount not less than RMB 25 million and not exceeding RMB 50 million through centralized bidding within a period of up to 3 months from the board's approval of the repurchase plan [2][1] - The repurchase is in compliance with relevant laws and regulations, including the "Regulations on the Repurchase of Shares by Listed Companies" and the "Self-Regulatory Guidelines for Listed Companies No. 7 - Share Repurchase" [2][1] - The supervisory board has confirmed that the repurchase plan is in the interest of all shareholders, particularly minority shareholders, and that the decision-making process is legal and compliant [2][1]
五芳斋: 浙江五芳斋实业股份有限公司关于以集中竞价交易方式回购股份的预案
Zheng Quan Zhi Xing· 2025-06-27 16:27
Core Viewpoint - The company plans to repurchase shares through a centralized bidding process, with a total amount between RMB 35 million and RMB 70 million, aimed at employee stock ownership plans or equity incentives [1][3][4]. Summary by Relevant Sections Repurchase Plan Details - The repurchase amount is set between RMB 35 million and RMB 70 million [1][4]. - The funding source for the repurchase will be the company's own funds [1][4]. - The maximum repurchase price is capped at RMB 29.12 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [1][4][8]. - The repurchase will be conducted via centralized bidding [1][4]. - The duration for the repurchase is set for a maximum of 12 months from the board's approval date [1][4]. Shareholder and Management Plans - As of the announcement date, there are no plans for share reduction by major shareholders, including directors, supervisors, and those holding more than 5% of shares, in the next 3 to 6 months [2][11]. - The board's decision to proceed with the repurchase was unanimously approved with 9 votes in favor [2][3]. Purpose and Impact of the Repurchase - The repurchased shares will be used for employee stock ownership plans or equity incentives; any unutilized shares after 36 months will be canceled [1][4][12]. - The repurchase is expected to enhance the company's long-term value and employee motivation without significantly impacting daily operations or financial stability [9][10]. Financial Metrics - As of March 31, 2025, the company's total assets were RMB 2.653 billion, with net assets of RMB 1.674 billion and a debt-to-asset ratio of 36.85% [9][10]. - The total repurchase amount represents approximately 2.64% of total assets and 4.18% of net assets [9][10]. Regulatory Compliance - The repurchase plan complies with relevant laws and regulations, including the Company Law and Securities Law [3][5]. - The board has authorized management to handle all necessary procedures related to the repurchase [12][14].
格林美: 关于2024年年度权益分派实施后调整回购股份价格上限的公告
Zheng Quan Zhi Xing· 2025-06-27 16:24
Overview of Share Buyback Plan - The company has approved a share buyback plan using its own funds and special loan funds, with a total amount between 100 million RMB and 200 million RMB, and a maximum buyback price of 9.93 RMB per share [1][2] - The buyback shares will be used for employee stock ownership plans and to reduce registered capital, with at least 50% of the repurchased shares for capital reduction [1] Adjustment of Buyback Price Cap - Following the annual profit distribution plan approved on May 19, 2025, the company will distribute a cash dividend of 0.66 RMB per 10 shares, with no stock bonus [2] - The buyback price cap has been adjusted from 9.93 RMB to 9.86 RMB per share due to the cash dividend distribution [4][5] Financial Implications - The total cash dividend will reduce the per-share cash dividend to approximately 0.0656731 RMB, affecting the calculation of the ex-dividend price [3] - As of the announcement date, the company has utilized 136,743,597 RMB for buybacks, leaving a remaining buyback fund of 63,256,403 RMB, which can repurchase approximately 6,415,456 shares [5]
东方生物: 关于以集中竞价方式回购公司股份的方案
Zheng Quan Zhi Xing· 2025-06-27 16:24
证券代码:688298 证券简称:东方生物 公告编号:2025-028 浙江东方基因生物制品股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: ● 回购股份金额:不低于人民币 2,500 万元(含),不超过人民币 5,000 万元(含); ● 回购股份资金来源:本次回购股份的资金来源全部为自有资金或自筹资金(含 股票回购专项贷款资金等); 公司控股股东安吉福浪莱进出口贸易有限公司、Fangs Holdings Limited Liability Company、安吉涌威创业投资合伙企业(有限合伙)(即公司董事、高 级管理人员的持股平台)在回购期间、未来 3 个月、未来 6 个月不存在减持公司 股份的计划。 本次回购股份提议人、公司实际控制人、董事长方剑秋先生,公司实际控制 人、董事、总经理方效良先生,公司实际控制人方炳良先生,在回购期间、未来 3 个月、未来 6 个月不存在减持公司股份的计划。 财务负责人、副总经理俞锦洪先生表示,在未来 3 个月、未来 6 个月,满足 减持法律法规相关要求的前提下 ...
能特科技: 关于回购股份实施结果暨股份变动的公告
Zheng Quan Zhi Xing· 2025-06-27 16:24
证券代码:002102 证券简称:能特科技 公告编号:2025-065 三、回购方案的实施对公司的影响 本次回购不会对公司经营、财务、研发、债务履行能力和未来发展产生重大 影响,不会导致公司控制权发生变化,也不会改变公司的上市公司地位,股权分 布情况仍然符合上市条件。 四、回购股份期间相关主体买卖公司股票情况 湖北能特科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整,没有虚假 记载、误导性陈述或者重大遗漏。 湖北能特科技股份有限公司(以下简称"公司")于 2025 年 2 月 11 日召开 了第七届董事会第二十七次会议、第七届监事会第二十一次会议,于 2025 年 2 月 27 日召开了 2025 年第二次临时股东大会,审议通过了《关于回购股份并注销 的议案》,同意公司使用自有资金及自筹资金通过深圳证券交易所交易系统以集 中竞价交易方式回购部分公司股份,回购资金总额不低于人民币 30,000 万元(含), 不超过人民币 50,000 万元(含),回购价格不超过人民币 3.90 元/股(含),实 施期限为自公司股东大会审议通过回购方案之日起 12 个月内(即 2025 年 2 月 回购 ...
国科军工: 关于实施回购股份注销暨股份变动的公告
Zheng Quan Zhi Xing· 2025-06-27 16:12
证券代码:688543 证券简称:国科军工 公告编号:2025-038 一、回购股份的基本情况 公司于 2024 年 2 月 7 日召开第三届董事会第六次会议,审议通过了《关于 以集中竞价交易方式回购股份方案的议案》。本次回购的股份将在未来适宜时机 全部用于员工持股计划或者股权激励,回购资金总额不低于人民币 7,000 万元 (含),不超过人民币 13,000 万元(含),回购价格拟不超过人民币 58 元/股(含), 回购期限自公司董事会审议通过本次回购股份方案之日起 12 个月内。具体内容 详见公司分别于 2024 年 2 月 9 日、2024 年 2 月 27 日在上海证券交易所网站 (www.sse.com.cn)披露的《第三届董事会第六次会议决议公告》(公告编号: 司股份的回购报告书》(公告编号:2024-011)。 首次实施回购公司股份,2025 年 2 月 7 日,公司完成回购,已实际回购公司股 份 1,666,533 股,占公司总股本 175,701,557 股的比例为 0.9485%,回购成交的最 高价为 50.00 元/股,最低价为 36.31 元/股,支付的资金总额为人民币 76,125, ...
盛美上海:已回购44.34万股 使用资金总额5001.23万元
news flash· 2025-06-27 11:05
盛美上海公告,公司于2025年6月27日通过上海证券交易所交易系统以集中竞价交易方式首次回购股份 44.34万股,占公司总股本4.41亿股的0.10%,回购价格区间为110.81元/股至115.49元/股,累计使用资金 5001.23万元(不含交易费用)。本次回购符合相关法律法规及公司回购方案,后续将继续根据市场情况实 施回购并及时披露进展。 ...
五芳斋:拟以3500万元-7000万元回购股份
news flash· 2025-06-27 09:43
Core Viewpoint - The company plans to repurchase shares with a budget of 35 million to 70 million yuan, with a maximum repurchase price of 29.12 yuan per share, aimed at enhancing long-term incentive mechanisms and boosting investor confidence [1] Summary by Relevant Sections - **Share Repurchase Details** - The company intends to repurchase between 120.19 thousand and 240.38 thousand shares, which represents 0.61% to 1.21% of the total share capital [1] - The repurchase period is set for up to 12 months from the date of board approval, with funding sourced from the company's own capital [1] - **Purpose of the Repurchase** - The repurchase is designed to implement an employee stock ownership plan or equity incentive, thereby promoting the company's long-term sustainable development [1]
迈威生物: 迈威生物关于以集中竞价交易方式回购股份方案的公告
Zheng Quan Zhi Xing· 2025-06-26 16:51
Core Viewpoint - The company plans to repurchase its shares through a centralized bidding process on the Shanghai Stock Exchange, with a total repurchase amount between RMB 25 million and RMB 50 million, aimed at employee stock ownership plans or equity incentives [1][2][5]. Summary by Sections Repurchase Plan Details - Total repurchase amount: RMB 25 million to RMB 50 million [1][5] - Source of funds: Company’s own funds and/or special loans for stock repurchase [1][12] - Maximum repurchase price: RMB 35.00 per share, not exceeding 150% of the average trading price over the last 30 trading days prior to the board's decision [2][12] - Repurchase method: Centralized bidding on the Shanghai Stock Exchange [1][6] - Repurchase period: Within 12 months from the board's approval [2][6] Purpose and Justification - The repurchase aims to enhance investor confidence, improve shareholder returns, and establish a long-term incentive mechanism for employees [5][12]. - The company believes its stock is undervalued based on its operational performance and future growth potential [8][12]. Shareholder and Management Actions - Major shareholders and management have no plans to reduce their holdings in the next 3 to 6 months [2][14]. - The proposal for the repurchase was initiated by the chairman and CEO, reflecting confidence in the company's future [15]. Financial Impact - The repurchase will not significantly impact the company's operations, finances, or future development, as the funds are manageable within the company's financial structure [13][16]. - The expected number of shares to be repurchased ranges from approximately 71,430 to 142,860 shares, representing 0.18% to 0.36% of the total share capital [5][7]. Regulatory Compliance - The repurchase plan complies with relevant regulations and does not require shareholder approval as it was passed by the board [5][6]. - The company will adjust the repurchase terms if there are changes in regulations during the repurchase period [7][12].
赛科希德: 赛科希德关于股份回购实施结果暨股份变动的公告
Zheng Quan Zhi Xing· 2025-06-26 16:47
Core Viewpoint - The company, Beijing Saike Xide Technology Co., Ltd., has successfully completed its share repurchase plan, acquiring a total of 2,172,456 shares, which represents 2.0467% of its total share capital, with a total expenditure of approximately 51.1 million yuan [1][3]. Summary by Sections 1. Share Repurchase Plan - The share repurchase plan was first disclosed on June 28, 2024, proposed by Chairman Wu Shiming [1]. - The implementation period for the repurchase is from June 26, 2024, to June 25, 2025 [1]. - The expected repurchase amount ranges from 50 million yuan to 100 million yuan, with a maximum repurchase price set at 34.5 yuan per share [1]. 2. Implementation Status - As of June 25, 2025, the company has completed the share repurchase, acquiring a total of 2,172,456 shares [3]. - The highest purchase price was 29.00 yuan per share, while the lowest was 19.92 yuan per share [3]. - The total amount paid for the repurchase was 51,100,586.60 yuan, excluding transaction fees [3]. 3. Compliance and Impact - The company adhered to relevant laws and regulations during the repurchase process, and the execution of the plan aligns with the originally disclosed details [3]. - The share repurchase will not significantly impact the company's daily operations, financial status, or future development [3]. 4. Shareholder Structure - Before the repurchase, the company had 106,142,400 shares, all of which were unrestricted circulating shares [4]. - After the repurchase, the number of unrestricted circulating shares decreased to 103,969,944 [4]. 5. Future Plans for Repurchased Shares - The repurchased shares will be used for employee stock ownership plans or equity incentive plans in the future [4]. - If the company does not utilize the repurchased shares within three years, the unutilized shares will be canceled according to relevant laws and regulations [4].